Riskpilot← Back to searchSign inGet full accessDolphimed A/S
A/SActiveCVR 42539023Pilestræde 58, 6.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20211 employees
Revenue 2024
DKK -163K
-92% vs 2023
EBITDA margin
100.0%
+92% vs 2023
Equity ratio
-194.6%
Financial strength
Net profit 2024
DKK -5,2M
+20% vs 2023
| Revenue | DKK -163K | -92% |
| EBITDA | DKK -163K | +92% |
| Net profit | DKK -5,2M | +20% |
| Total assets | DKK 16,1M | -5% |
| Equity | DKK -31,3M | -20% |
| Employees | 1 | — |
Legal name
Dolphimed A/S
CVR number
42539023
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. juli 2021
Share capital
DKK 400.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse eller af en direktør.
Company purpose
Selskabets formål er at udvikle og kommercialisere medicinsk teknologi samt hermed beslægtet virksomhed.
Address
Pilestræde 58, 6.
Phone
+4533193319
Email
ole.johan.gillebo@dolphitech.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | -15.469 | -1.932 | -163 |
| Staff expenses | -1.057 | -1 | -0 |
| EBITDA | -16.525 | -1.933 | -163 |
| Depreciation & amort. | -463 | -694 | -694 |
| EBIT | -16.988 | -2.627 | -858 |
| Net financials | -3.143 | -3.808 | -4.311 |
| Profit before tax | -20.131 | -6.435 | -5.169 |
| Tax | -0 | -0 | -0 |
| Net profit | -20.131 | -6.435 | -5.169 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 23.179 | 16.994 | 16.106 |
| Equity | -19.731 | -26.166 | -31.335 |
| Long-term debt | 39.207 | 43.127 | 47.440 |
| Short-term debt | 3.703 | 33 | 0 |
| Total debt | 42.910 | 43.160 | 47.440 |
EBITDA margin
-16337300.0%
This company
15.8%
Market median
-103400733% vs market
20222024
Equity ratio
-194.6%
This company
38.2%
Market median
-609% vs market
20222024
Return on equity
-516894700.0%
This company
18.4%
Market median
-2809210426% vs market
20222024
Net profit margin
-516894700.0%
This company
8.1%
Market median
-6381416149% vs market
20222024
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20222024
Debt / equity
1.51×
This company
0.62×
Market median
-144% vs market
20222024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HL Management | Management | 2021 | — | — |
PA Management | Management | 2021 | — | — |
OJ Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2023 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
UL | Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2022 | |
| Individual | 25.0% | 25.0% | 2022 | |
| Individual | 5.0% | 5.0% | 2022 | |
| Individual | 100.0% | 100.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dolphimed A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrik Lassen | Management | 0 companies |
| Peter Andreas Stakemann | Management | 0 companies |
| Ole Johan Gillebo | Chief Executive Officer | 0 companies |
| Per Christian Methi | Chairman | 0 companies |
| Thomas Jeffrey Malherbes Gullacksen | Chairman | 0 companies |
| Spiros Kotopoulis | Board of Directors | 0 companies |
| Ulf Lund | Board of Directors | 0 companies |